Browsing by Subject "Biosimilars"
Now showing items 1-6 of 6
-
Biologics and Biosimilars as Treatment Options for Psoriasis
(Brac University, 2022-02)Psoriasis is a common chronic skin disease stemming from a systemic inflammatory disorder. It affects more than 7.5 million people in the United States and an estimated 125 million people worldwide. It is an immune-mediated ... -
Biosimilars: A revolution for biologics in the pharmaceutical industry
(BRAC University, 2017-08-23)The high demand for and resulting financial success of biopharmaceutical products over the last three decades have seen the door open for close copies of these biological products. Popularly termed as biosimilars, these ... -
Concepts and challenges of biosimilars to mitigate the oncology drug expenses
(Brac University, 2021-02)Biosimilars is way more likely to genuine generic drugs of the innovator. Time to time expiry of generic drugs helps manufacturer to think about biosimilars which has wide cost effectiveness as well as expanded patient ... -
Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
(Brac University, 2021-12)ABP-501 is a biosimilar of Adalimumab (Humira) and a tumor necrosis factor-alpha inhibitor that is responsible for inflammatory effects on the body. ABP-501 is equally effective against moderate to severe rheumatoid arthritis ... -
Targeted therapeutic options in the treatment of Breast Cancer
(Brac University, 2022-02)The recent application of targeted therapies such as biologics, biosimilars, and other targeted biological agents in the treatment of diverse subtypes of breast cancer has been facilitated by the decoding of the human ... -
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars
(Brac University, 2021-04)Angiogenesis is one of the pivotal factors contributing to the development and metastasis of non small cell lung cancer which is one of the most commonly diagnosed types of lung cancer. Bevacizumab, a monoclonal antibody ...
